You are currently on the new version of our website. Access the old version .

2,315 Results Found

  • Article
  • Open Access
9 Citations
4,890 Views
9 Pages

Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience

  • Silvia Giordano,
  • Paolo Dapavo,
  • Michela Ortoncelli,
  • Elena Stroppiana,
  • Anna Verrone,
  • Pietro Quaglino,
  • Simone Ribero and
  • Luca Mastorino

5 December 2023

Background: Interleukin 23 (IL-23) inhibitors, such as guselkumab, risankziumab, and tildrakizumab, have proved to be highly effective and safe for psoriasis treatment either in bio-naïve or bio-experienced patients. A substantial proportion of...

  • Review
  • Open Access
5 Citations
7,474 Views
16 Pages

8 May 2025

Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disease characterized by recurrent pustules, erythema, and scaling on the palms and soles, leading to a significantly reduced quality of life. Although PPP shares some immunopathological fe...

  • Article
  • Open Access
2 Citations
1,760 Views
13 Pages

IL-6R Inhibitors and Gastrointestinal Perforations: A Pharmacovigilance Study and a Predicting Nomogram

  • Shupeng Zou,
  • Mengling Ouyang,
  • Qian Cheng,
  • Xuan Shi,
  • Yazheng Zhao and
  • Minghui Sun

17 December 2024

Objective IL-6R inhibitors are widely used in many inflammation-related diseases, especially so during the COVID-19 pandemic. However, their relationship with gastrointestinal perforations (GIPs) has been reported more and more. We comprehensively an...

  • Article
  • Open Access
10 Citations
4,232 Views
14 Pages

Novel Small Molecule Inhibitors Targeting the IL-6/STAT3 Pathway or IL-1β

  • Jihye Yoo,
  • Darong Kim,
  • Jiyoung Park,
  • Young-Kook Kim,
  • Hea-Young Park Choo and
  • Hyun Ae Woo

22 April 2022

Development of small molecules that inhibit inflammatory cytokines is a desirable strategy for the treatment of inflammatory diseases such as rheumatoid arthritis (RA). Following up a previous study, we synthesized 10 novel compounds with a 2,5-diami...

  • Article
  • Open Access
17 Citations
4,014 Views
9 Pages

Skin Mycobiome of Psoriasis Patients is Retained during Treatment with TNF and IL-17 Inhibitors

  • Yuta Koike,
  • Sayaka Kuwatsuka,
  • Katsutaro Nishimoto,
  • Daisuke Motooka and
  • Hiroyuki Murota

Background: Biological treatment relieves refractory skin lesions in patients with psoriasis; however, changes in the fungal microbiome (the mycobiome) on the skin are unclear. Methods: The skin mycobiome of psoriasis patients treated with TNF inhibi...

  • Review
  • Open Access
24 Citations
14,909 Views
19 Pages

The Role of IL-23 Inhibitors in Crohn’s Disease

  • Jacopo Fanizza,
  • Ferdinando D’Amico,
  • Francesca Lusetti,
  • Ernesto Fasulo,
  • Mariangela Allocca,
  • Federica Furfaro,
  • Alessandra Zilli,
  • Tommaso Lorenzo Parigi,
  • Simona Radice and
  • Laurent Peyrin-Biroulet
  • + 2 authors

30 December 2023

Promoting a Th17 pathogenic response, the interleukin (IL)-23 pathway is crucial in the pathophysiology of inflammatory bowel disease (IBD). With a favorable safety profile, ustekinumab, a monoclonal antibody targeting the shared p40 component of IL-...

  • Review
  • Open Access
1 Citations
2,922 Views
15 Pages

28 August 2025

Rheumatoid arthritis (RA) is a systemic autoimmune disease that, beyond joint destruction, contributes to neuropsychiatric symptoms such as depression, anxiety, and cognitive impairment. These symptoms are often underrecognized despite their major im...

  • Article
  • Open Access
440 Views
12 Pages

Impact of Brodalumab on Serum Levels of IL-6, IL-17A, IFN-α, IFN-γ, and TNF-α in Patients with Psoriasis Who Failed Treatment with TNF-α Inhibitors

  • Lucia Medjedovic,
  • Admir Vižlin,
  • Ylva Andersch Björkman,
  • Anna-Maj Albertsson,
  • Sukanya Raghavan,
  • Martin Gillstedt and
  • Amra Osmancevic

Psoriasis is a chronic, immune-mediated inflammatory skin disorder that significantly impacts patients’ quality of life. While TNF-α inhibitors are frequently used to treat moderate-to-severe cases, not all patients respond adequately. Br...

  • Article
  • Open Access
908 Views
18 Pages

Disproportionality Analysis of Adverse Events Associated with IL-1 Inhibitors in the FDA Adverse Event Reporting System (FAERS)

  • Jingjing Lei,
  • Zhuoran Lou,
  • Yuhua Jiang,
  • Yue Cui,
  • Sha Li,
  • Jinhao Hu,
  • Yeteng Jing and
  • Jinsheng Yang

1 December 2025

Background: Interleukin-1 (IL-1) inhibitors are approved for the treatment of various inflammatory diseases associated with immune system abnormalities. However, large-scale real-world studies to assess their security are still limited. Therefore, a...

  • Article
  • Open Access
1,003 Views
17 Pages

15 October 2025

Breast cancer gene 1 (BRCA1) is a tumor suppressor gene essential for DNA repair, and its mutations are linked to aggressive breast cancers with poor prognosis. While poly (ADP-ribose) polymerase (PARP) inhibitors benefit some patients with BRCA1-mut...

  • Review
  • Open Access
11 Citations
5,062 Views
21 Pages

An Insight on the Possible Association between Inflammatory Bowel Disease and Biologic Therapy with IL-17 Inhibitors in Psoriasis Patients

  • Olguța Anca Orzan,
  • Cristian George Țieranu,
  • Andrei Ovidiu Olteanu,
  • Alexandra Maria Dorobanțu,
  • Anca Cojocaru,
  • Mara Mădălina Mihai,
  • Liliana Gabriela Popa,
  • Ana Maria Gheorghiu,
  • Călin Giurcăneanu and
  • Ana Ion

Psoriasis is a chronic, inflammatory, multisystemic disease which affects approximately 2–3% of the population globally, whose onset is triggered by genetic and environmental factors which activate both dendritic cells and keratinocytes, result...

  • Review
  • Open Access
6 Citations
5,417 Views
13 Pages

Generalized Pustular Psoriasis (GPP) is a rare and severe subtype of psoriasis that significantly impacts patients’ quality of life. Until recently, no specific treatment modalities were available, and treatment for GPP followed the guidelines...

  • Article
  • Open Access
1,411 Views
18 Pages

Effect of Statins and Renin–Angiotensin–Aldosterone System Inhibitors on IL-6 Levels in COVID-19 Patients

  • Laura Pereckaite,
  • Neringa Vaguliene,
  • Agne Vitkauskaite,
  • Astra Vitkauskiene and
  • Daiva Urboniene

26 October 2024

Background/Objectives: Severe clinical course and mortality from COVID-19 are mostly associated with increased concentrations of IL-6 and IL-10. Findings from clinical trials suggest that both statins and renin–angiotensin–aldosterone sys...

  • Article
  • Open Access
14 Citations
3,569 Views
12 Pages

Chronic inflammation contributes significantly to the development and progression of atherosclerosis. However, the factors that lead to an inflammatory imbalance towards a proinflammatory state are not yet fully understood. The CRP rs1800947, TNFA rs...

  • Review
  • Open Access
1,377 Views
8 Pages

22 October 2025

Interleukin-23 (IL-23) inhibitors have rapidly become an essential component of the therapeutic armamentarium for inflammatory bowel disease (IBD). Risankizumab, mirikizumab, and guselkumab share broadly similar pharmacokinetic and pharmacodynamic pr...

  • Article
  • Open Access
4 Citations
9,140 Views
6 Pages

21 February 2006

Bioassay-guided isolation from the ethanol extract of a marine sponge Theonella sp. collected in Palau yielded bistheonellide A, which strongly inhibited the colony formation of Chinese hamster V79 cells (EC50 = 6.8 nM). Bistheonellide A is an actinp...

  • Article
  • Open Access
8 Citations
3,654 Views
9 Pages

High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study

  • Beatriz Frade-Sosa,
  • Andrés Ponce,
  • Virginia Ruiz-Esquide,
  • Maria Jesús García-Yébenes,
  • Rosa Morlá,
  • Nuria Sapena,
  • Julio Ramirez,
  • Ana Belen Azuaga,
  • Juan Camilo Sarmiento and
  • Juan D. Cañete
  • + 2 authors

Background: We examined whether high-sensitivity CRP (hsCRP) reflected the inflammatory disease status evaluated by clinical and ultrasound (US) parameters in RA patients receiving IL-6 receptor antibodies (anti-IL-6R) or JAK inhibitors (JAKi). Metho...

  • Article
  • Open Access
17 Citations
6,083 Views
17 Pages

IL3RA-Targeting Antibody–Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic Malignancies

  • Dennis Kirchhoff,
  • Beatrix Stelte-Ludwig,
  • Hans-Georg Lerchen,
  • Antje Margret Wengner,
  • Oliver von Ahsen,
  • Pascale Buchmann,
  • Stephan Märsch,
  • Christoph Mahlert,
  • Simone Greven and
  • Lisa Dietz
  • + 5 authors

20 November 2020

IL3RA (CD123) is the alpha subunit of the interleukin 3 (IL-3) receptor, which regulates the proliferation, survival, and differentiation of hematopoietic cells. IL3RA is frequently expressed in acute myeloid leukemia (AML) and classical Hodgkin lymp...

  • Article
  • Open Access
1 Citations
2,851 Views
16 Pages

New, Low–Molecular Weight Chemical Compounds Inhibiting Biological Activity of Interleukin 15

  • Piotr Krzeczyński,
  • Małgorzata Dutkiewicz,
  • Oliwia Zegrocka-Stendel,
  • Bartosz Trzaskowski and
  • Katarzyna Koziak

Chronic overproduction of IL–15 contributes to the pathogenesis of numerous inflammatory and autoimmune disorders. Experimental methods used to reduce the cytokine activity show promise as potential therapeutic approaches to modify IL–15...

  • Article
  • Open Access
6 Citations
2,688 Views
12 Pages

Platelet Microvesicles, Inflammation, and Coagulation Markers: A Pilot Study

  • Antonio Gidaro,
  • Alessandro Palmerio Delitala,
  • Roberto Manetti,
  • Sonia Caccia,
  • Mark J. Soloski,
  • Giorgio Lambertenghi Deliliers,
  • Dante Castro,
  • Mattia Donadoni,
  • Arianna Bartoli and
  • Giuseppe Sanna
  • + 2 authors

4 December 2023

Background: Platelet “Microvesicles” (MVs) are studied for their role in blood coagulation and inflammation. The study aimed to establish if MVs are related to age, plasma levels of inflammation, coagulation, and fibrinolysis markers in h...

  • Review
  • Open Access
11 Citations
7,888 Views
14 Pages

Hidradenitis suppurativa (HS), recognized as a chronic and debilitating skin disease, presents significant challenges in both diagnosis and treatment. This review explores the clinical manifestations, genetic landscape, and molecular mechanisms under...

  • Review
  • Open Access
43 Citations
8,728 Views
18 Pages

State of Art of Idiosyncratic Drug-Induced Neutropenia or Agranulocytosis, with a Focus on Biotherapies

  • Emmanuel Andrès,
  • Noel Lorenzo Villalba,
  • Abrar-Ahmad Zulfiqar,
  • Khalid Serraj,
  • Rachel Mourot-Cottet and
  • Jacques-Eric Gottenberg

1 September 2019

Introduction: Idiosyncratic drug-induced neutropenia and agranulocytosis is seldom discussed in the literature, especially for new drugs such as biotherapies outside the context of oncology. In the present paper, we report and discuss the clinical da...

  • Review
  • Open Access
58 Citations
14,654 Views
32 Pages

New and Emerging Targeted Therapies for Hidradenitis Suppurativa

  • Adela Markota Čagalj,
  • Branka Marinović and
  • Zrinka Bukvić Mokos

Hidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory skin disease deriving from the hair follicles. The formation of inflammatory nodules, abscesses, fistulas, and sinus tracts is characterized by a large inflow of key pro-inflammatory...

  • Feature Paper
  • Review
  • Open Access
1,047 Views
13 Pages

The Fast-Evolving Landscape of Treatments for Calcium Pyrophosphate Deposition Disease

  • Vicky Tai,
  • Charlotte Jauffret,
  • Nicola Dalbeth and
  • Tristan Pascart

Calcium pyrophosphate deposition (CPPD) disease is a consequence of the immune response to the pathological accumulation of calcium pyrophosphate (CPP) crystals within joints. This clinically heterogeneous condition can cause significant disability,...

  • Review
  • Open Access
1 Citations
9,454 Views
31 Pages

New Interleukin-23 Antagonists’ Use in Crohn’s Disease

  • Laura Biskup,
  • Jan Semeradt,
  • Jagoda Rogowska,
  • Wiktoria Chort,
  • Łukasz Durko and
  • Ewa Małecka-Wojciesko

22 March 2025

Crohn’s disease (CD) is a chronic inflammatory condition of the digestive tract, driven by an imbalance in immune system regulation, where proinflammatory interleukin-23 (IL-23) plays an essential role. Selective new IL-23 inhibitors, including...

  • Article
  • Open Access
1 Citations
1,260 Views
31 Pages

Targeting Neuronal Nitric Oxide Synthase (nNOS) as a Novel Approach to Enhancing the Anti-Melanoma Activity of Immune Checkpoint Inhibitors

  • Anika Patel,
  • Shirley Tong,
  • Kate Lozada,
  • Amardeep Awasthi,
  • Richard B. Silverman,
  • Jennifer Totonchy and
  • Sun Yang

Background and Objectives: Neuronal nitric oxide synthase (nNOS) overexpressed in melanoma plays a critical role in disease progression. Our previous studies demonstrated that nNOS inhibitors exhibited potent anti-melanoma activity and regulated PD-L...

  • Review
  • Open Access
8 Citations
14,833 Views
15 Pages

Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules

  • Francesco Ferrara,
  • Chiara Verduci,
  • Emanuela Laconi,
  • Andrea Mangione,
  • Chiara Dondi,
  • Marta Del Vecchio,
  • Veronica Carlevatti,
  • Andrea Zovi,
  • Maurizio Capuozzo and
  • Roberto Langella

14 September 2024

Psoriasis is a persistent, inflammatory condition affecting millions globally, marked by excessive keratinocyte proliferation, immune cell infiltration, and widespread inflammation. Over the years, therapeutic approaches have developed significantly,...

  • Review
  • Open Access
62 Citations
9,462 Views
19 Pages

NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases

  • Eleonora Mezzaroma,
  • Antonio Abbate and
  • Stefano Toldo

12 February 2021

Virtually all types of cardiovascular diseases are associated with pathological activation of the innate immune system. The NACHT, leucine-rich repeat (LRR), and pyrin domain (PYD)-containing protein 3 (NLRP3) inflammasome is a protein complex that f...

  • Article
  • Open Access
15 Citations
3,917 Views
13 Pages

IL-17A Is the Critical Cytokine for Liver and Spleen Amyloidosis in Inflammatory Skin Disease

  • Shohei Iida,
  • Takehisa Nakanishi,
  • Fumiyasu Momose,
  • Masako Ichishi,
  • Kento Mizutani,
  • Yoshiaki Matsushima,
  • Ai Umaoka,
  • Makoto Kondo,
  • Koji Habe and
  • Yoshifumi Hirokawa
  • + 5 authors

Systemic amyloidosis is recognized as a serious complication of rheumatoid arthritis or inflammatory bowel disease, but also of inflammatory skin disease. However, the detailed molecular mechanism of amyloidosis associated with cutaneous inflammation...

  • Article
  • Open Access
4 Citations
1,979 Views
17 Pages

Plasmatic Inactive IL-18 Predicts a Worse Overall Survival for Advanced Non-Small-Cell Lung Cancer with Early Metabolic Progression after Immunotherapy Initiation

  • Serena Janho dit Hreich,
  • Olivier Humbert,
  • Tanguy Pacé-Loscos,
  • Renaud Schiappa,
  • Thierry Juhel,
  • Marius Ilié,
  • Victoria Ferrari,
  • Jonathan Benzaquen,
  • Paul Hofman and
  • Valérie Vouret-Craviari

14 June 2024

The aim of this study was to assess the potential value of circulating active and inactive IL-18 levels in distinguishing pseudo and true tumor progression among NSCLC patients receiving immune checkpoint inhibitor treatments (ICIs). Methods: This an...

  • Article
  • Open Access
2 Citations
1,457 Views
18 Pages

Co-Inhibition of PARP and STAT3 as a Promising Approach for Triple-Negative Breast Cancer

  • Changyou Shi,
  • Li Pan,
  • Satomi Amano,
  • Mei-Yi Wu,
  • Chenglong Li and
  • Jiayuh Lin

17 July 2025

Triple-negative breast cancer (TNBC) is a highly aggressive subtype known for its rapid metastatic potential. Despite its severity, treatment options for TNBC remain limited. Olaparib, an FDA-approved PARP inhibitor, has been used to treat germline B...

  • Review
  • Open Access
1 Citations
2,491 Views
16 Pages

Monoclonal Antibodies and Small-Molecule Therapies for Lichen Planus: Targeted Immunomodulation and Emerging Evidence

  • Francois Rosset,
  • Nadia Sciamarrelli,
  • Luca Mastorino,
  • Valentina Pala,
  • Sara Boskovic,
  • Eleonora Bongiovanni,
  • Orsola Crespi,
  • Yingying Liao,
  • Simone Ribero and
  • Pietro Quaglino

17 September 2025

Background/Objectives: Lichen planus (LP) is a chronic inflammatory disease of autoimmune origin, affecting the skin and mucous membranes. While corticosteroids and immunosuppressants are traditionally used, many cases remain refractory or intolerant...

  • Review
  • Open Access
985 Views
22 Pages

Beyond Lipids and Platelets: A Review of Anti-Inflammatory Strategies in Secondary Prevention of Acute Coronary Syndromes

  • Girish Pathangey,
  • Mohamed N. Allam,
  • Mahmoud H. Abdelnabi,
  • Dan Sorajja,
  • Floyd David Fortuin,
  • Kwan S. Lee and
  • Mayurkumar D. Bhakta

7 November 2025

Despite advances in lipid-lowering and antithrombotic therapy, patients with acute coronary syndromes remain at elevated risk for recurrent events due to persistent atherosclerotic inflammation. This review evaluates inflammation as a therapeutic tar...

  • Article
  • Open Access
4 Citations
2,405 Views
9 Pages

19 June 2022

(1) Background: To date, the response of patients with rheumatoid arthritis (RA) to the various biologic DMARD available cannot be predicted due to a lack of reliable biomarkers. Based on our preliminary work on tmTNF reverse signaling, we developed...

  • Article
  • Open Access
18 Citations
5,286 Views
12 Pages

Compositional Alteration of Gut Microbiota in Psoriasis Treated with IL-23 and IL-17 Inhibitors

  • Yu-Huei Huang,
  • Lun-Ching Chang,
  • Ya-Ching Chang,
  • Wen-Hung Chung,
  • Shun-Fa Yang and
  • Shih-Chi Su

26 February 2023

Alterations in the gut microbiota composition and their associated metabolic dysfunction exist in psoriasis. However, the impact of biologics on shaping gut microbiota is not well known. This study aimed to determine the association of gut microorgan...

  • Review
  • Open Access
67 Citations
11,388 Views
28 Pages

Chemoresistance is a major cause of recurrence and death from T-cell acute lymphoblastic leukemia (T-ALL), both in adult and pediatric patients. In the majority of cases, drug-resistant disease is treated by selecting a combination of other drugs, wi...

  • Article
  • Open Access
1 Citations
2,685 Views
20 Pages

Prognostic Role of Human Leukocyte Antigen Alleles and Cytokine Single-Nucleotide Polymorphisms in Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitor Drugs

  • Samuel Kinde Birru,
  • Ilias Doxiadis,
  • Rawleigh Howe,
  • Tsehayneh Kelemu,
  • Saifu Hailu Chala,
  • Abdulaziz Sherif,
  • Fisihatsion Tadesse,
  • Aster Tsegaye,
  • Amha Gebremedhin and
  • Claudia Lehmann

2 June 2024

Tyrosine kinase inhibitor (TKI) drugs have significantly improved chronic myeloid leukemia (CML) outcomes. Neopeptides from CML cells may induce specific immune responses, which are crucial for deep molecular (DMR) and treatment-free remission (TFR)....

  • Article
  • Open Access
39 Citations
7,740 Views
16 Pages

IL-24 Negatively Regulates Keratinocyte Differentiation Induced by Tapinarof, an Aryl Hydrocarbon Receptor Modulator: Implication in the Treatment of Atopic Dermatitis

  • Yen Hai Vu,
  • Akiko Hashimoto-Hachiya,
  • Masaki Takemura,
  • Ayako Yumine,
  • Yasutaka Mitamura,
  • Takeshi Nakahara,
  • Masutaka Furue and
  • Gaku Tsuji

10 December 2020

Skin barrier dysfunction, including reduced filaggrin (FLG) and loricrin (LOR) expression, plays a critical role in atopic dermatitis (AD) development. Since aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor, mediates keratinoc...

  • Case Report
  • Open Access
31 Citations
14,509 Views
22 Pages

COVID-19, caused by the novel severe acute respiratory coronavirus 2 (SARS-CoV-2), emerged in Wuhan, China, in 2019 and has resulted in the current pandemic. The disease continues to pose a major therapeutic challenge. Patient mortality is ultimately...

  • Review
  • Open Access
10 Citations
4,158 Views
18 Pages

Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management

  • Dani Ran Castillo,
  • Won Jin Jeon,
  • Daniel Park,
  • Bryan Pham,
  • Chieh Yang,
  • Bowon Joung,
  • Jin Hyun Moon,
  • Jae Lee,
  • Esther G. Chong and
  • Kiwon Park
  • + 4 authors

In the past decade, targeted therapies for solid tumors, including non-small cell lung cancer (NSCLC), have advanced significantly, offering tailored treatment options for patients. However, individuals without targetable mutations pose a clinical ch...

  • Article
  • Open Access
2 Citations
2,125 Views
19 Pages

Cilomilast Modulates Rhinovirus-Induced Airway Epithelial ICAM-1 Expression and IL-6, CXCL8 and CCL5 Production

  • Jie Zhu,
  • Michael R. Edwards,
  • Simon D. Message,
  • Luminita A. Stanciu,
  • Sebastian L. Johnston and
  • Peter K. Jeffery

20 November 2024

Background: Cilomilast, a phosphodiesterase-4 (PDE4) selective inhibitor, has anti-inflammatory effects in vitro and in vivo and reduces COPD exacerbations. We tested the hypothesis that cilomilast inhibits virus-induced airway epithelial intercellul...

  • Article
  • Open Access
1,007 Views
16 Pages

Drug Metabolism and Pharmacokinetics of Oxazolo[4,5-c]quinoline Analogs as Novel Interleukin-33 Inhibitors

  • Hayoung Jeon,
  • Geonhee Jang,
  • Min-A Ban,
  • Sang-Hyun Son,
  • Youngjoo Byun and
  • Kiho Lee

Background/Objectives: Interleukin-33 (IL-33) is crucial in immune-mediated diseases like asthma. Targeting the IL-33/ST2 pathway holds therapeutic promise. This study characterized the pharmacokinetics (PK) and metabolism of KB-1517 and KB-1518, new...

  • Article
  • Open Access
1 Citations
1,725 Views
16 Pages

Gene–Environment Interaction: Small Deletions (DELs) and Transcriptomic Profiles in Non-Melanoma Skin Cancer (NMSC) and Potential Implications for Therapy

  • Farzana Jasmine,
  • Armando Almazan,
  • Yuliia Khamkevych,
  • Maria Argos,
  • Mohammad Shahriar,
  • Tariqul Islam,
  • Christopher R. Shea,
  • Habibul Ahsan and
  • Muhammad G. Kibriya

10 January 2025

Arsenic (As) is a risk factor for non-melanoma skin cancer (NMSC). From a six-year follow-up study on 7000 adults exposed to As, we reported the associations of single-nucleotide variation in tumor tissue and gene expression. Here, we identify the as...

  • Review
  • Open Access
3 Citations
5,085 Views
10 Pages

Restoration of Skin Barrier Abnormalities with IL4/13 Inhibitors and Jak Inhibitors in Atopic Dermatitis: A Systematic Review

  • Isidora Chatzigeorgiou,
  • Dimitra Koumaki,
  • Efstratios Vakirlis,
  • Ilias Papadimitriou and
  • Stamatios Gregoriou

22 August 2024

Background and Objectives: Atopic dermatitis is a chronic inflammatory skin disorder with a significant burden on patients’ quality of life. This systematic review aims to evaluate the restoration of skin barrier abnormalities with interleukin-...

  • Article
  • Open Access
1,123 Views
12 Pages

Geboes Histopathology Score Grade 3 Subclassification Predicts Treatment Response in Active Ulcerative Colitis

  • Ichitaro Horiuchi,
  • Akira Horiuchi,
  • Kaori Horiuchi,
  • Shun Watanabe,
  • Tsuyoshi Terashima and
  • Ken Sugimoto

13 October 2025

Background: The growing number of ulcerative colitis (UC) treatments has complicated the selection process. We hypothesized that the degree of epithelial neutrophilic infiltration, which is a hallmark of interleukin-23 (IL-23) pathway activation, cou...

  • Review
  • Open Access
42 Citations
13,010 Views
16 Pages

The Treatment with Interleukin 17 Inhibitors and Immune-Mediated Inflammatory Diseases

  • Laura Țiburcă,
  • Marius Bembea,
  • Dana Carmen Zaha,
  • Alexandru Daniel Jurca,
  • Cosmin Mihai Vesa,
  • Ioana Adela Rațiu and
  • Claudia Maria Jurca

IL-17 inhibitors (IL-17i) are medicines used to treat dermatological and rheumatic diseases They belong to a class of medicines called biological disease-modifying anti-rheumatic drugs (bDMARDs). This class of drugs has had a major impact on the ther...

  • Review
  • Open Access
10 Citations
5,598 Views
25 Pages

Targeting IL-8 and Its Receptors in Prostate Cancer: Inflammation, Stress Response, and Treatment Resistance

  • Shauna McClelland,
  • Pamela J. Maxwell,
  • Cristina Branco,
  • Simon T. Barry,
  • Cath Eberlein and
  • Melissa J. LaBonte

8 August 2024

This review delves into the intricate roles of interleukin-8 (IL-8) and its receptors, CXCR1 and CXCR2, in prostate cancer (PCa), particularly in castration-resistant (CRPC) and metastatic CRPC (mCRPC). This review emphasizes the crucial role of the...

  • Article
  • Open Access
2,424 Views
11 Pages

Anti-TNFα Drugs and Interleukin Inhibitors: Epidemiological and Pharmacovigilance Investigation in COVID-19 Positive Patients

  • Zaira Maraia,
  • Tony Mazzoni,
  • Marco Bruno Luigi Rocchi,
  • Denise Feliciani,
  • Maria Chiara Romani,
  • Giovanna Acciarri,
  • Stefania Rafaiani and
  • Isidoro Mazzoni

27 October 2022

Cytokine patterns and immune activation in patients with Coronavirus 2019 (COVID-19) seem to resemble the case of rheumatoid arthritis (RA), psoriasis and inflammatory bowel disease (IBD). Biological drugs, such as anti-tumor necrosis factor α...

  • Article
  • Open Access
4 Citations
3,073 Views
20 Pages

Novel Function of Cancer Stem Cell Marker ALDH1A3 in Glioblastoma: Pro-Angiogenesis through Paracrine PAI-1 and IL-8

  • Zhen Chen,
  • Rainer Will,
  • Su Na Kim,
  • Maike Anna Busch,
  • Nicole Dünker,
  • Philipp Dammann,
  • Ulrich Sure and
  • Yuan Zhu

4 September 2023

Hyper-angiogenesis is a typical feature of glioblastoma (GBM), the most aggressive brain tumor. We have reported the expression of aldehyde dehydrogenase 1A3 (ALDH1A3) in proliferating vasculature in GBM patients. We hypothesized that ALDH1A3 may act...

  • Case Report
  • Open Access
2 Citations
6,666 Views
13 Pages

28 January 2023

The incidence of psoriasis, an intractable long-lasting inflammatory skin disease, is increasing and has many complications and comorbidities. Approximately 14% of patients have psoriatic arthritis (PsA). Rheumatoid arthritis (RA) is not a rare disea...

of 47